CA3221689A1 - A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product - Google Patents
A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product Download PDFInfo
- Publication number
- CA3221689A1 CA3221689A1 CA3221689A CA3221689A CA3221689A1 CA 3221689 A1 CA3221689 A1 CA 3221689A1 CA 3221689 A CA3221689 A CA 3221689A CA 3221689 A CA3221689 A CA 3221689A CA 3221689 A1 CA3221689 A1 CA 3221689A1
- Authority
- CA
- Canada
- Prior art keywords
- tasquinimod
- amount
- compound
- capsules
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183481.7 | 2021-07-02 | ||
| EP21183481 | 2021-07-02 | ||
| PCT/EP2022/068063 WO2023275248A1 (en) | 2021-07-02 | 2022-06-30 | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3221689A1 true CA3221689A1 (en) | 2023-01-05 |
Family
ID=76764937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3221689A Pending CA3221689A1 (en) | 2021-07-02 | 2022-06-30 | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277693A1 (https=) |
| EP (1) | EP4363404A1 (https=) |
| JP (1) | JP2024524158A (https=) |
| KR (1) | KR20240029029A (https=) |
| CN (1) | CN117500790A (https=) |
| AU (1) | AU2022303084A1 (https=) |
| CA (1) | CA3221689A1 (https=) |
| IL (1) | IL309486A (https=) |
| MX (1) | MX2023014668A (https=) |
| WO (1) | WO2023275248A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024306742A1 (en) * | 2023-06-28 | 2025-12-04 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of mpn |
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| CN105367492B (zh) * | 2014-08-28 | 2018-07-03 | 杭州普晒医药科技有限公司 | 他喹莫德的晶型及其制备方法、其药物组合物和用途 |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
-
2022
- 2022-06-30 AU AU2022303084A patent/AU2022303084A1/en active Pending
- 2022-06-30 CN CN202280043401.8A patent/CN117500790A/zh active Pending
- 2022-06-30 JP JP2023578067A patent/JP2024524158A/ja active Pending
- 2022-06-30 US US18/571,472 patent/US20240277693A1/en active Pending
- 2022-06-30 EP EP22741222.8A patent/EP4363404A1/en active Pending
- 2022-06-30 MX MX2023014668A patent/MX2023014668A/es unknown
- 2022-06-30 KR KR1020247002056A patent/KR20240029029A/ko active Pending
- 2022-06-30 CA CA3221689A patent/CA3221689A1/en active Pending
- 2022-06-30 IL IL309486A patent/IL309486A/en unknown
- 2022-06-30 WO PCT/EP2022/068063 patent/WO2023275248A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014668A (es) | 2024-01-12 |
| EP4363404A1 (en) | 2024-05-08 |
| KR20240029029A (ko) | 2024-03-05 |
| WO2023275248A1 (en) | 2023-01-05 |
| AU2022303084A1 (en) | 2024-01-25 |
| US20240277693A1 (en) | 2024-08-22 |
| CN117500790A (zh) | 2024-02-02 |
| IL309486A (en) | 2024-02-01 |
| JP2024524158A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6604941B2 (ja) | Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤 | |
| EP3056205A1 (en) | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof | |
| US20240307398A1 (en) | Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient | |
| US20240277693A1 (en) | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product | |
| CN102351857A (zh) | 盐酸托烷司琼化合物 | |
| TW201328725A (zh) | Ｎ－甲基－２－［３－（（ｅ）－２－吡啶－２－基－乙烯基）－１ｈ－吲唑－６－基硫烷基］苯甲醯胺之藥學組成物 | |
| CN102367252A (zh) | 一种盐酸托烷司琼化合物 | |
| JP2021532193A (ja) | 生物学的に利用可能な経口剤形 | |
| PT2288341T (pt) | Utilização de uma matriz para administração oral de magnésio de libertação prolongada e composição contendo esta matriz | |
| US20260076908A1 (en) | Plurality of tasquinimod particles and use thereof | |
| JP7301883B2 (ja) | Ｈｃ－１１１９製剤及びその製造方法と使用 | |
| SA08290417B1 (ar) | تركيبة دوائية ثابتة تشمل ملح فينفلونين القابل للذوبان فى الماء | |
| RU2456987C1 (ru) | Способ получения желатиновых капсул на основе 3,31- дииндолилметана | |
| CN121969357A (zh) | Mrtx1133药物组合物 | |
| CN105646520A (zh) | 一种稳定的艾日布林化合物 | |
| CN111217757B (zh) | 一种恩杂鲁胺化合物及其药物组合物制剂 | |
| CN114224832A (zh) | 一种恩杂鲁胺注射剂及其制备方法和应用 | |
| WO2021099901A1 (en) | Stable topical pharmaceutical composition | |
| CN107200719B (zh) | 990207-22-1一种晶vii型物质、其制法和其药物组合物与用途 | |
| CN107200720B (zh) | 一种晶ⅱ型物质、其制法和其药物组合物与用途 | |
| RU2448700C1 (ru) | Желатиновые капсулы на основе 3,31-дииндолилметана и эпикатехин-3-галлата и способ их получения | |
| JP2022500441A (ja) | 結晶性（ｒ）−５−カルバモイルピリジン−３−イル−２−メチル−４−（３−（トリフルオロメトキシ）ベンジル）ピペラジン−１−カルボキシレート、組成物、及びその使用方法 | |
| WO2025195333A1 (en) | Pharmaceutical formulation of erbb2 inhibitors | |
| KR20250092209A (ko) | 이미다조피라진 유도체의 결정형 및 이의 제조 방법과 응용 | |
| CN106995381A (zh) | 一种琥珀酸美托洛尔晶型及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250618 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250618 |